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Abstract 
Peptides 31D and VF 13, corresponding to the rabies virus nucleo- and glycoproteins, respectively, vigorously stimulate T helper cells 
of the appropriate specificity. Earlier we showed how internal and external glycosylation affects the major histocompatibility complex 
molecule (MHC)-binding ability and conformation of these T-cell epitopes (Otvos et al. (1994) Biochim. Biophys. Acta 1224, 68-76; 
Otvos et al. (1995) Biochim. Biophys. Acta 1267, 55-64). In the current report, we examined the T-helper cell stimulatory ability after 
introduction of a new set of post-translational modifications. To obtain general information concerning the effects of amino acid 
side-chain modifications on other biochemical properties of protein fragments, we studied the serum stability and the conformation of the 
31D and VF13 peptides. We found that the extent of the reduction of the T-cell stimulatory activity depends upon the location in the 
sequence of the host amino acid residue. Generally, B-linked sugars in mid-chain positions had a greater inhibitory effect than u-linked 
sugars attached to identical araino acids. In a case where mid-chain glycosylation just marginally reduced the T-cell stimulatory activity, 
the B-linked glycopeptide was significantly more resistant to serum proteases. This finding suggests that addition of B-linked 
carbohydrates might be superior to the addition of a-linked sugars for vaccine development, and generally for peptide agonist drug 
design. In addition, data presented here provide the first documentation that phosphorylation a d sulfation of tyrosine residues may retain 
the MHC-binding ability and T-cell stimulatory activity of class II epitopes. The sulfated and the phosphorylated 31D peptides exhibited 
considerably increased serum stabilitY compared to the unmodified parent peptide. Finally, all post-translational modifications destabi- 
lized the dominant ~x-helical or turn structures of the peptides presented in aqueous trifluoroethanol mixtures. While the circular 
dichroism spectra of the a- and B-linked VFI3 glycopeptides with monosaccharides were almost indistinguishable, the structure of the 
glycopeptides depended upon the length of the sugar moiety. Significantly, incorporation of sulfate or phosphate groups resulted in 
identical peptide conformations. 
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I. Introduction 
Many proteins undergo post-translational modifications 
with a corresponding alteration in their biological and 
biochemical properties. Synthetic peptides can be good 
models to study the local conformational nd functional 
changes following attachment of the side-chain moiety 
including carbohydrate, phosphate and sulfate groups. Up 
to now, however, the synthetic apability to produce these 
* Corresponding author. Fax: + 1 (215) 8985821. 
modified protein fragments was very limited. With the 
recent availability of appropriately protected amino acid 
building blocks, the chemical synthesis of phosphopep- 
tides, sulfopeptides, and some glycopeptides i no longer 
an obstacle to the proposed studies. Comprehensive analy- 
sis of the peptide structure and function upon addition of 
novel side-chain appendages i further prompted by the 
dual role the modified peptides play in biochemistry and 
biotechnology. First, they can be used to analyze the 
fragments of post-translationally modified proteins that 
occur in nature. Second, the introduction of hydrophilic 
and protease-resistant sugar [1,2] and phosphate [3,4] 
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groups promises to improve the physical and biological 
properties of peptide drug leads. A comparative analysis of 
the effects of such modifications i therefore long overdue. 
We have studied the ability of some phosphorylated and 
glycosylated peptides to bind to major histocompatibility 
complex (MHC) determinants and to stimulate T-cells with 
appropriate specificity. Internal phosphorylation f a serine 
residue of an epitope recognized by CD4 ÷ and CD8 ÷ 
T-cells results in diminished T-cell stimulatory activity, 
although the phosphopeptide is still capable of binding to 
the restricting elements [5]. The effect of tyrosine phospho- 
rylation on the T-cell stimulatory activity of class II epi- 
topes has not yet been studied. However, in a recent study, 
Arsequell and coworkers demonstrate hat phosphorylation 
of a tyrosine residue does not interfere with H-2D b class I 
MHC-binding, in contrast with phosphorylation f a threo- 
nine that eliminates the binding to all class I MHC alleles 
tested [6]. The same group shows that another class I 
MHC-binding peptide can be modified by both a- and 
13-1inked serine glycosylation as well as 13-1inked as- 
paragine glycosylation without affecting its binding to the 
MHC, provided the modifications do not involve amino 
acids located at MHC anchor positions [7]. In our experi- 
ence, glycosylation of class II epitopes either increases the 
antigenic potency through increasing the stability of the 
peptides when the sugar is attached to the N-terminus [8], 
or reduces the antigenic potency if the sugar is incorpo- 
rated in mid-chain position [9]. In the latter case the 
reduction depends upon the anomeric onfiguration of the 
added sugar; glycopeptides with 13-1inked sugars to as- 
paragine residues (the natural anomeric onfiguration of 
carbohydrates in extracellular N-glycoproteins [10]) lose 
their ability to bind to class II MHC more than glycopep- 
tides with a-linked sugars to threonine residues [9]. The 
experimental results were later confirmed by molecular 
modeling of the MHC:peptide complexes [11]. However, 
these studies compare a- vs. [3-1inked glycopeptides when 
the carbohydrates are incorporated into amino acids in the 
same position of the peptides, but are attached to different 
amino acid hosts (13- to Asn and a- to Thr). In the current 
report we examine the T-helper cell stimulatory activity of 
the glycopeptides when the same threonine residues are 
glycosylated with either tx- or 13-1inked sugars. We extend 
the analysis of the metabolic stability to internally glycosy- 
lated and tyrosine phosphorylated peptides as indicated by 
the functional T-cell assay after incubation of the peptides 
in human serum. Our models are immunodominant epi- 
topes of the rabies virus nucleo- and glycoproteins. Peptide 
31D, AVYTRIMMNGGRLKR binds to murine class II 
MHC I-E k and peptide VF13, VVEDEGCTNLSGF binds 
to I-A k. 
Glycosylation of asparagine residues in synthetic pep- 
tides breaks helices and results in the formation of 
reverse-turns [12]. Turns themselves are usually stabilized 
or their geometry is modified after glycosylation [13]. 
These rules may also apply to O-glycosylation [9,13,14], 
although the resulting glycopeptide structures are less or- 
dered than after glycosylation of asparagine [9]. Increasing 
the length of carbohydrates from mono- to disaccharide 
results in just marginally different conformations for N- 
glycosylated peptides as evidenced by circular dichroism 
(CD) and Fourier-transform infrared (FT-IR) spectroscopy 
[12], but qualitatively different conformations for O-glyco- 
peptides as evidenced by nuclear magnetic resonance 
(NMR) [15]. We investigated whether the NMR-derived 
conformational differences between O-glycopeptides with 
different length of sugars can be recorded by CD and 
whether the anomeric onfiguration of the attached sugars 
play any role in the final secondary structures. This latter 
problem is especially important because while extracellular 
O-glycoproteins carry a- [16], intracellular O-glyco- 
proteins carry 13-1inked carbohydrate side-chains [17]. 
Phosphorylation f serine residues imilarly breaks helices 
[18], but does not appear to stabilize any special peptide 
conformation [12], except maybe in cases associated with 
the pathological aggregation of phosphoproteins, such as 
those in Alzheimer's disease [19]. In contrast, CD and 
FT-IR reveals that tyrosine phosphorylation can stabilize 
both a-helices [20] or 13-pleated sheets [21] indicating a 
possible distinct role of the phosphotyrosine r sidues in 
signal transduction. 
In spite of the identification of the sulfate binding sites 
in numerous ulfoproteins [22] and the extended research 
on the synthesis [23] and biological assay [24] of sulfopep- 
tides (e.g., cholecystokinin, hirudin, gastrin), the general 
effect of incorporating sulfate moieties on peptide confor- 
mation and metabolic stability has, to our knowledge, not 
been reported. In this paper we study these biochemical 
properties as well as the T-helper cell stimulatory activity 
of a sulfated analogue of peptide 31D. 
2. Materials and methods 
The peptides used in this study are listed in Table 1. 
2.1. Synthetic pept ides 
Peptides were assembled on solid-phase using a Milli- 
gen 9050 automated peptide synthesizer employing stan- 
dard Fmoc-methodology [25]. The synthesis of the Fmoc- 
Asn-13(GlCT)-OH and its incorporation i to N-terminal po- 
sitions of peptides has been previously detailed [26]. 
Fmoc-Tyr(PO~H2)-OH was prepared according to Ot- 
tinger et al. [27], Fmoc-Tyr(SO3H)-OH • Ba was purchased 
from Bachem Bioscience (King of Prussia, PA). Fmoc- 
Thr-13(Gal)-OH [28] was kindly provided by Professor 
Raniero Rocchi (University of Padova). Glycoamino acids, 
phosphotyrosine and sulfotyrosine were incorporated in the 
same manner as unmodified amino acids, except that 
Fmoc-Thr-a(Ac4Gal-I ~ 313-Ac2GalNAc)-OH, purchased 
from Bachem California (Torrance, CA) and Fmoc-Thr- 
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et(Ac3GalNAc)-OH purchased from Oxford Glycosystems 
(Rosedale, NY) were coupled in stoichiometric amounts to 
reduce cost. Peptides were cleaved from the solid support 
by trifluoroacetic a id (TFA) in the presence of thioanisole 
as scavenger. Deacetylation of the sugar hydroxyl groups 
was accomplished by a 2-rain treatment with 0.1 M NaOH 
[9,29]. In a most recent paper [29], we thoroughly analyzed 
different deacetylation methods during the synthesis of an 
O-glycosylated antibiotic peptide. Significantly, if the pep- 
tide was treated with diluted NaOH followed by immediate 
neutralization, only minor (1.5%) 13-elimination occurred. 
Moreover, capillary electrophoresis of the final product 
revealed only a single peak, indicating the lack of diastere- 
omer formation (racemization) during the deacetylation 
step [29]. After cleavage, unmodified peptides were puri- 
fied, and glycopeptides, the phosphopeptide, the sulfopep- 
tide and the contaminating (unmodified, amino acid 
deleted) analogs were separated by reversed-phase high 
performance liquid chromatography (RP-HPLC). The final 
products were characterized by amino acid analysis and 
laser desorption mass spectrometry (MS). Table 1 lists the 
RP-HPLC retention times .and the MS data. 
2.2. Proliferation assay (for VF13 peptides) 
Irradiated C3H/He mouse spenocytes (5.105) in 100 
Ixl of Dulbecco's modified Eagle's medium (DMEM) sup- 
plemented with 10 -s M 2-mercaptoethanol and 2% FBS 
in 96-well round-bottom icrotiter plates were co-cultured 
with antigen at the indicated concentration in 25 ixl medium 
for 30 min at 37°C. D2rab.gp T-cells (2- 10 4) were  then 
added in 50 I~1 of medium. Proliferation of T-cells was 
measured 48 h later by a ,5 h [3H]thymidine pulse [30]. 
2.3. Cytokine release assay (for 31D peptides) 
The 9C5.D8 T-cell hybridoma was tested for recogni- 
tion of peptides presented by irradiated H-2 compatible 
splenocytes by a lymphokine release assay as described 
[301. 
2.4. Serum stability 
To assess the metabolic stability of the peptides, these 
were incubated in 50% human serum in a concentration f
0.1 mg/ml for 3 h or overnight. One batch was kept at 
37°C to promote degradation and the other control batch 
was kept for the same period of time at 4°C. The serum- 
preincubated peptides were subsequently diluted in culture 
medium and subjected to the T-cell stimulation assays as 
described in Section 2.2 and Section 2.3. 
2.5. CD 
CD spectra were taken on a Jasco J-720 instrument at 
room temperature in a 0.2 mm path-length cell. Double 
distilled water and spectroscopy grade trifluoroethanol 
(TFE) were used as solvents. Peptide concentration was 
approximately 0.5 mg/ml, as determined by quantitative 
HPLC. The CD spectra shown are baseline-corrected and 
smoothed by the algorithm provided by Jasco. The glyco- 
sylated VF13T peptides exhibited a time-dependent con- 
formational change, as the dimerization of the peptide in 
solution progressed. The CD spectra shown in Fig. 5 
represent the conformation of the monomers. Similar to 
our earlier eports, the spectral contributions of the O-gly- 
cosides [9,13] and the tyrosine-phosphates [20] were not 
subtracted. Accordingly, the CD contribution of the tyro- 
sine sulfate was not considered. In fact, no major perturba- 
tion of the CD below 225 nm is expected to occur due to 
the presence of a single tyrosine side-chain [31] and its 
contribution of intensity to the spectrum of the 15-mer 
31D is negligible. Mean residue ellipticity [®]mR is ex- 
pressed in deg. cm2/dmol using mean residue weights 
calculated from the molecular weight divided by the num- 
ber of amino acids in the peptides. 
Table 1 
Synthetic peptides and their characterization 
Peptide Sequence Side-chain modification (X) RP-HPLC LD-MS * (M + H) + 
retention time (rain) 
31D AVYTRIMMNGGRLKR 22.6 1765 
31D-YP AVY(X)TR1MMNGGRLKR Phosphate 21.3 1848 
31D-YS AVY(X)TRIMMNGGRLKR Sulfate (barium salt) 22.0 1847 
31D-Tct-GalGalNAc AVYT(X)RIMMNGGRLKR Gal(131 ~ 3)GalNAc(ct ~ O) 20.2 2132 
31D-T[3-Gal AVYT(X)RIMMNGGRLKR Gal(13 ~ O) 21.6 1930 
VF 13N VVEDEGCTNLSGF 25.5 1370 
VF13N-Tet-GalGalNAc VVEDEGCT(X)NLSGF Gal(131 --, 3)GalNAc(et ~ O) 25.1 1755 
VF13N-TI3-Gal VVEDEGCT(X)NLSGF Gal(13 --* O) 21.8 1532 
VF 13T VVEDEGC'Iq'LSGF 26.1 1359 
VF13T-T8ct-GalGalNAc VVEDEGCTI~(X)LSGF GaI(IM ~ 3)GalNAc(ct ~ O) 25.4* * 1743 
VF13T-T8et-GalNAc VVEDEGCTT(X)LSGF GalNAc(c~ ~ O) 21.8 1583 
VF 13T-T8~-Gal VVEDEGCTT(X)LSGF Gal([3 ~ O) 21.4 1556 
(M + Na) + 
(M + Na) + 
(M + Na) + 
(M + K) + 
* The accuracy of the LD-MS instrument used at the examined mol wt. range is + 4 Da. 
* * Retention time data taken from [9] by using a somewhat slower eluting HPLC system. 
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3. Results 
3.1. T-cell stimulation 
The T-cell stimulatory activity of glycosylated VFI3 
peptides was measured at 5 Ixg/ml. This high peptide 
concentration is suboptimal for side-chain unmodified pep- 
tides VF13N and VF13T owing to the generally observ- 
able 'pro-zone' activity of T-cell epitopic peptides and 
peptides recognized by monoclonal ntibodies. However, a 
high peptide concentration is required to obtain any de- 
tectable activity of the glycosylated peptides on the D2 
rab.gp T cell line (raised against rabies virus glycoprotein 
unglycosylated on Asn37) [9]. As shown in Fig. 1, attach- 
ment of c~-linked sugars to both peptides VFI3N and 
VF13T considerably decreased the T-cell stimulatory ac- 
tivity. This effect was more prominent for the peptide pair 
VF13N - VF13N-ToL-GalGalNAc where the glycopeptide 
was only slightly more stimulatory than the background 
control. Nevertheless, c~-glycosylated peptide VF13T- 
T8a-GalGalNAc retained some stimulatory activity for the 
T-cells. In contrast, peptides carrying a 13-1inked monosac- 
charide on identical amino acids (VF13N-TI3-Gal and 
VFI3T-T813-Gal) lost their T-cell stimulatory activity al- 
most entirely. This is probably because 13-glycosylated 
VF13 peptides have a very limited ability to bind to the 
MHC determinant [9,11 ]. 
We studied the serum stability of peptides at two tem- 
peratures. The resistance of the peptides to serum proteases 
was probed by preincubating the peptides with human 
serum at 37°C before the T-cell proliferation assay (see 
next chapter). As short incubation at 4°C is not expected to 
considerably affect peptide stability, the T-cell stimulation 
of peptides treated with human serum at low temperatures 
serves as a starting point to access the inherent T-cell 
stimulatory activity of the peptides during identical assay 
conditions. For these experiments analogues of peptide 
3000 
31D were used. As with the VF13 peptides, incorporation 
of carbohydrates to the threonine located in mid-chain 
position of peptide 31D resulted in decreased T-cell stimu- 
latory activity at low teperature (Fig. 2). Also in agreement 
with data obtained with the VF13 peptides, the 31D-de- 
rived glycopeptide carrying an a-linked sugar moiety 
(3 ! D-Ta-GalGalNAc) retained a greater T-cell stimulatory 
activity than the glycopeptide carrying a B-linked side- 
chain substitution (31D-TI3-Gal) (Fig. 2). Major differ- 
ences between the 31D and the VF13-derived peptides 
were; (a) the 3 ID-glycopeptides were generally much more 
stimulatory than the VFl3-glycopeptides, and (b) even the 
13-glycosylated 31D-peptide retained considerable activity. 
Incorporation of phosphate or sulfate side-chains to the 
tyrosine residue, located in mid-chain position of peptide 
31D, did not interfere with the T-cell stimulation at 4°C 
(Fig. 3). In fact, at low peptide concentrations the modified 
peptides exhibited higher T-cell stimulatory activity than 
the unmodified peptide. This was probably due to some 
remaining serum protease activity on the unmodified pep- 
tide during the assay procedure. The remaining protease 
activity at 4°C was generally apparent when the peptides 
were incubated overnight, and during those reaction condi- 
tions most of the peptides entirely lost their T-cell stimula- 
tory activity. The phosphopeptide and the sulfopeptide 
exhibited indistinguishable T-cell stimulatory activity after 
3 h at 4°C (Fig. 3). While the T-cell stimulation of peptide 
31D carrying palmitic acids at the N-terminus without any 
serum treatment slightly exceeded those of peptides 3I D- 
YP and 31D-YS, the phosphopeptide and the sulfopeptide 
reproducibly stimulated the T-cells to an almost identical 
extent (data not shown). 
3.2. Serum stability at 37°C 
Both T-cell agonist and antagonist peptide drug leads 
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Fig. 1. Response of T-cells to VFI3 peptides and glycopeptides. [3H]Thymidine incorporation was measured in cpm as described in Section 2. The 
standard eviation of triplicated samples is represented by the error bars. 
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Fig. 2. Response of T-cells to peptide 31D and its glycosylated analogs after incubation in 50% human serum for 3 h. Solid traces a and d represent 
unmodified peptide 31D; broken traces b and e represent the ct-glycosylated peptide 31D-Tct-GalGalNAc; dots and dashes c and f represent the 
13-glycosylated peptide 31D-T[3-Gal. Traces a -c  indicate preincubation at4°C; traces d - f  indicate preincubation at 37°C. 
temperatures compared to the unmodified parent analogs. 
To test whether internal glycosylation provided T-cell 
modulatory peptide leads, we applied the serum stability 
assay to the 31D-derived glycopeptides. We selected the 
31D peptides over the VFI3 peptides, because the former 
glycopeptides retained much higher T-cell stimulatory ac- 
tivity without serum treatment. Preincubation of the pep- 
tides in 50% human serum considerably influenced their 
T-cell stimulation. Unmodified peptide 31D was affected 
the most; it went from most stimulatory at 4°C to least 
stimulatory at 37°C (Fig. 2). ot-glycosylated peptide 31D- 
Tot-GalGalNAc was margJinally more resistant to preincu- 
bation than peptide 3 ID. [3-glycosylated peptide 31D-TI3- 
Gal, however, exhibited remarkably high serum stability 
after 3 h (a customary end point of our studies), and was 
clearly superior to the other two peptides (Fig. 2). More- 
over, after incubation at 4°C overnight, only the 13-glyco- 
sylated peptide stimulated the cells more than the back- 
ground (data not shown). 
The phosphorylated and the sulfated tyrosine residue 
(third amino acid in the 31D sequence) is located one 
residue closer to the N-terminus (a frequent peptidase 
cleavage site [2]) than the threonine, and consequently the 
phosphopeptide and the sulfopeptide were expected to 
exhibit more pronounced protease resistance than the gly- 
copeptides. Indeed, both the phosphorylated and the sul- 
fated 31D analogs remained considerably more stimulatory 
to the T-cells after 3 h incubation in 50% human serum at 
40 
8 ~ 20 .E 
-T 10 
4 o C 
3TC 
0.1 1 10 
Peptide concentration (ug/rnl) 
Fig. 3. Response of T-cells to :liD peptides after incubation in 50% human serum for 3 h. Solid traces a and d represent the unmodified peptide 31D; 
broken traces b and e represent the tyrosine-phosphorylated p ptide 31D-YP; dots and dashes c and f represent the tyrosine-sulfated peptide 31D-YS. 
Traces a--c indicate preincubaion at 4°C; traces d - f  indicate preincubation at 37°C. 
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Fig. 4. CD spectra of peptide VF13T and its Thr8-glycosylated analogs. 
Solid line: unmodified peptide VF13T; dots: VF13T-T8a-GalNAc (a-lin- 
ked monosaccharide); dashes: VF13T-T8ct-GalGalNAc (a-linked disac- 
charide); dots and dashes: VF13T-T813-Gal ([3-1inked monosaccharide). 
37°C than their unmodified parent analogue (Fig. 3). The 
sulfopeptide remained comparatively ess affected by the 
proteases and this is unlikely to be due to any size 
difference between the phosphate and the sulfate anions 
(the S-O distance in the sulfate anion is 149 pm, and the 
P-O distance in the phosphate anion is 152 pm). It needs to 
be emphasized that these assays, by nature, are highly 
complex and variable, as can be seen in the comparison of 
the shapes of the curves and the values for peptide 31D in 
Figs. 2 and 3. The relative serum stability and T-cell 
stimulatory activity of the peptides, however, indicate the 
trends among the properties of the peptide analogs exam- 
ined. 
3.3. Peptide conformation 
Internal O-glycosylation generally destabilized the heli- 
cal (31D) or turn (VF13T) structures of the unmodified 
peptides in aqueous TFE mixtures [8,9]. In the current 
study, we examined the conformation-modifying effects of 
~- vs. 13-glycosylation f Thr8 in peptide VFI3T, and the 
effect on the CD spectra of the length of the sugars that are 
attached to Thr8 in peptide VF13T, or Thr4 in peptide 
31D. Unmodified peptide VF13T exhibited a type C CD 
spectrum in 50% TFE (Fig. 4), characteristic of type I (III) 
13-turns [32] or type I (IID and type II 13-turn mixtures [33]. 
The blueshift of the 202 nm band from that observed in 
ideal type C spectra (204-206 nm) indicated some un- 
ordered contribution. Unordered peptides (or polypeptides 
with left-handed polyproline II structure) exhibit a strong 
negative band at or below 200 nm accompanied by a weak 
positive band above 210 nm [34]. The intensity of the 
negative 224 nm n~* band of peptide VFI3T was de- 
creased and that of the further blueshifted negative 'rrw* 
band (201 nm) was increased after addition of monosac- 
charides in either c~- or 13-anomeric onfiguration (Fig. 4), 
indicating a greater contribution of the unordered structure 
to the conformational equilibrium. The ratio of the 225-227 
nm:201-202 nm bands, the measure of ordered structure 
for helical or turn peptides, was 0.46 for the unmodified 
peptide, 0.21 for the a-linked glycopeptide, and 0.19 for 
the 13-1inked glycopeptide. The CD of the two monosac- 
charide-coupled glycopeptides were very similar including 
the identical wavelength of all of the bands. The only 
notable difference was that the whole spectrum of the 
oL-linked glycopeptide was slightly shifted to the positive 
direction. This shift was approx. 700 dog • cm 2/dmol  at 
the 7r ~r * bands which likely reflected the contribution of 
the single acetamido group present on the carbohydrate 
portion of the a-linked glycopeptide. The 13-1inked gly- 
copeptide lacks this functionality on the sugar moiety. The 
positive shift of glycopeptides carrying acetamido groups 
is documented by the CD of 1,2-diacetamido-l,2-dideoxy- 
13-o-glucopyranose, which compound exhibits a broad pos- 
itive band centered near 194 nm with an intensity, calcu- 
lated to the mean residue ellipticity of peptides the size of 
VF13, of approx. 2300 [12]. Taken together, the data 
indicated that addition of monosaccharides in either a- or 
in 13-anomeric onfiguration similarly destabilized the turn 
structure of peptide VFI3T. Nevertheless, turns were still 
significantly present in the conformational equilibrium for 
the glycopeptides carrying monosaccharides, but were al- 
most absent for the glycopeptide carrying the disaccharide 
side-chain. The negative 'rrar* band of glycopeptide 
VF13T-T8oL-GalGalNAc was further blueshifted to 199 
nm, and the positive 188 nm band nearly disappeared. This 
spectral feature, together with the almost zero-line crossing 
of the 216 nm band, characterized the CD as type U 
spectrum, and indicated that the peptide existed in pre- 
dominantly unordered conformation (Fig. 4). 
Incorporation of a mono- or a disaccharide to the 
threonine, as well as phosphorylation or sulfation of the 
tyrosine residue resulted in markedly decreased a-helical 
content of peptide 31D. Peptide 31D undergoes an un- 
ordered ~ o~-helix conformational transition when as- 
sayed in dilutions from water to TFE [35]. Compared to 
ideal a-helical peptides [31], in 50% TFE the CD curve 
intensity of 31D revealed a medium level of helicity [35] 
which was further supported by the 2 nm blueshift of the 
bands representing the "rrTr * transition (Fig. 5). Another 2 
nm blueshift, and decrease in the band intensities were 
detected when the monosaccharide was added in peptide 
31D-TIg-Gal (Fig. 5), indicating that glycosylation destabi- 
lized the helical structure. Elongation of the carbohydrate 
in glycopeptide 31D-Tc~-GalGalNAc further enhanced this 
effect without generating new conformers, as evidenced by 
the further decrease of all band intensities and unchanged 
wavelength of the peak maxima compared to the CD of the 
glycopeptide carrying the monosaccharide moiety (Fig. 5). 
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Fig. 5. CD spectra of peptide 31D and its modified analogs. Solid line (a)'. 
unmodified peptide 31D; dots and dashes dashes (b): threonine-glyco- 
sylated peptide 31D-TI3-Gal carding a monosaccharide side chain; dashes 
(c): threonine-glycosylated p ptide 31D-Tet-GalGalNAc arrying a disac- 
charide side-chain; dots (d): phosphopeptide 31D-YP; dots and short 
dashes (e): sulfopeptide 31D-YS. 
The a-helix content, measured at 208 nm [36], dropped 
approx. 20% after phosphorylation or sulfation of the 
tyrosine residue (Fig. 5). Accordingly, the 206 nm band 
and the zero-line crossing were bluesifted by 0.5-1 nm 
after the side-chain modifications. Owing to a possible 
minor contribution of the tyrosine side-chain at higher 
wavelengths, the determirmtion f the helix-content based 
on the higher energy "rr-tr' transition is more realistic than 
computer analyses of the CD curves that consider the 
entire CD spectra. Remarkably, the CD spectra of the 
phosphopeptide and the sulfopeptide were identical within 
the experimental error of the CD analysis and concentra- 
tion determination f the samples. 
4. Discussion 
These studies had two major goals: (a) to model and 
characterize various biochemical properties of glyco- 
protein, phosphoprotein and sulfoprotein fragments, and 
(b) to identify carbohydrate structures that are useful for 
peptide modification in general drug design, particularly 
that of T-cell agonists and antagonists. Earlier we found 
that internal glycosylation with a-linked carbohydrates 
reduces, while I~-linked carbohydrates fully diminishes the 
T helper cell stimulatory ability [8,9]. Here we further 
corroborated these observations by noting that the class II 
MHC-binding and T-ce][1 stimulatory ability of 13-1inked 
glycopeptides did not always decline to zero. When mea- 
surable T-cell activity remained after attachment of 13-1in- 
ked sugars, the design of T-cell antagonist peptides could 
benefit from the vast variety of available carbohydrate 
structures. Our serum stability assay indicated that ~-gly- 
cosylated 31D peptide was more resistant to serum pro- 
teases than the ot-glycosylated analogue. Moreover, the 
oMinked carbohydrate in peptide 31D-Tet-GalGalNAc was 
a disaccharide, while the 13-1inked carbohydrate in 31D- 
TI3-Gal was only a monosaccharide, indicating that the 
anomeric onfiguration had a greater effect on the serum 
stability than the length of the sugar (and presumably the 
distance from the cleavage site). In drug design terms, this 
means that if mid-chain glycosylation is planned, incorpo- 
ration of sugars in 13-anomeric configuration is more bene- 
ficial for T-cell antagonist production than in (x-anomeric 
configuration provided the 13-glycosylated peptide retains 
its ability to bind to the MHC. Because glycopeptides 
commonly are less stimulatory to the T-helper cells, inter- 
nal glycosylation is not advised for such agonist design. 
Stability studies in human serum are crucial in the investi- 
gation of the therapeutic utility of a peptide [2]. When the 
biological activity of a possible peptide drug lead can 
tolerate the addition of a carbohydrate side-chain, we 
recommend 13-1inked sugars over a-linked sugars. In gen- 
eral biochemistry terms our data indicate that peptide 
degradation is not only stereochemically, but also re- 
giospecifically controlled. Alternatively, if the cleavage of 
the sugar precedes the cleavage of the peptide bond, the 
human serum may retain more glycoprotein a-glycosydase 
activity than protein I~-glycosydase activity. Finally, if the 
peptide serum stability truly models the general intra- 
cellular protein and glycoprotein stability, our findings 
may explain why intracellular O-glycoproteins predomi- 
nantly carry ~-linked carbohydrates (extracellular O- 
glycoproteins carry a-linked carbohydrate moieties). 
The other possible way to generate T-cell antagonist 
glycopeptides is by adding long sugars to the termini [11]. 
Tetra and heptasaccharide moieties in influenza hemag- 
glutinin peptides N(GIc4)-CTLIDALLGDPH and 
N(GlcT)-CTLIDALLGDPH partially blocked the recogni- 
tion of the MHC:glycopeptide complex by the TcR [37]. 
Our preliminary results indicated a 5-15% reduction in the 
T-cell stimulatory activity of N-terminally glycosylated 
N-VF13 peptides, when the Asn(GicNAc) residue was 
replaced to Asn(Glc 7) (at 1-10 Ixg/ml). This alternative 
design of T-cell antagonists requires the identification of 
the minimal epitope, as blocking TcR recognition is depen- 
dent upon the distance between the N-terminal sugar and 
the TcR binding site [37], and the current synthetic 
methodology limits the length of the carbohydrate hat can 
be efficiently added. The approach is nevertheless attrac- 
tive, as N-terminal glycosylation is generally superior in 
terms of peptide stability [2]. 
The T-cell stimulatory ability of the VF13 derived 
glycopeptides were more sensitive to the anomeric onfig- 
uration of the attached sugars than those of the 31D 
glycopeptides. Moreover, in contrast with a serine-phos- 
phorylated, class II rabies peptide delineated from the 
nominal phosphoprotein [5], peptide 31D also retained its 
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T-cell stimulatory ability after either phosphorylation or
sulfation. This is especially surprising since the best align- 
ment of peptide 3 ID positions the tyrosine residue into the 
first binding pocket of murine class II MHC I-E k and the 
human equivalent HLA-DRI [11]. Since the phosphopep- 
tide and the sulfopeptide stimulated T-cells far better than 
the unmodified peptide after incubation in human serum, 
the conserved T-cell simulation cannot be explained by 
removal of the phosphate or sulfate group during the assay 
procedure. A more credible xplanation is that peptide 31D 
and its fragments or analogs can assume multiple positions 
in the MHC groove. This idea is supported by the seem- 
ingly unusual observation that short tri- and tetrapeptide 
fragments of peptide 31D can stimulate T-cells, albeit only 
upon significantly elevated peptide concentrations [30]. 
Nevertheless, the maintenance of class II MHC-binding 
and T-helper cell stimulatory ability after phosphorylation 
or sulfation indicated that the T-cell epitope repertoire of 
phospho- and sulfoproteins may include modified peptides. 
This finding may be of significance in signal transduction 
research where the study of phosphotyrosine-specific hu- 
moral immunity can be complemented with investigation 
of phosphotyrosine-specific ellular immune responses. 
Phosphorylation a d sulfation of the tyrosine residue in 
peptide 31D equally reduced the a-helicity of the unmodi- 
fied peptide. The similarity of the secondary structures can 
be explained by the approximately similar size of the 
phosphate and the sulfate anions. As no new conformers 
were generated and only the helix content decreased, the 
bulky side-chains appear to exclude part of the peptides 
from the helical network without any special interaction 
between the negatively charged side-chains and the peptide 
backbone. This is in contrast with earlier observations that 
suggest stabilizatory effects of tyrosine phosphorylation 
a-helices [20] and 13-pleated sheets [21]. Recognition of 
the importance of the conformation of phosphotyrosine- 
containing peptides in signal transduction [38] and in the 
design of inhibitors of these processes [39] therefore de- 
mands more caution in the treatment of this problem and 
requires the conformational nalysis of a statistically satis- 
fying number of tyrosine phosphorylated peptides. 
It was suggested that the monosaccharides in short 
O-glycopeptides do not interact with the peptide backbone 
and that their role is only to exclude certain conformations 
present in the non-glycosylated parent analogs [14]. The 
same research group used NMR to show that elongation of 
the carbohydrate to a disaccharide results in markedly 
different urn conformations compared to the glycopeptide 
carrying a monosaccharide moiety [15]. Both observations 
are supported by our current CD studies on turn peptides. 
The a- or [3-glycosylated versions of peptide VF13T 
studied here exhibited very similar CD spectra. These 
intermediate spectra represented a mixture of turn and 
unordered peptide conformations and were less ordered 
than those of the unmodified parent peptide. The contribu- 
tion of the unordered conformer was significantly in- 
creased after the carbohydrate side-chain was extended. 
This latter observation did not hold true for glycosylated 
analogs of the helical 31D peptide. Incorporation of the 
monosaccharide stabilized the helical conformation of 
31D, an effect which was more pronounced following 
elongation of the sugar but without generating new struc- 
tures. This is in contrast with the behavior of the turn-like 
peptides but is in accordance with the conformational 
analysis of N-glycosylated analogs of another helical ra- 
bies peptide [12]. In summary, it appears that the confor- 
mation-modifying effect of incorporating different sugar 
structures depends upon both the length of the sugar and 
the initial secondary structure of the peptide. 
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